Supernus Pharmaceuticals, Inc. (SUPN) Q2 2014 Earnings Results

Supernus Pharmaceuticals Beats on EPS, Stock Down 1.77%

Supernus Pharmaceuticals reported a strong EPS beat, indicating better-than-expected profitability. However, the stock fell by 1.77%, likely due to the absence of revenue figures and future guidance. Investors may be cautious as they await more detailed financial insights in upcoming reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.08	N/A	+143.72%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance. However, they did not provide specific guidance for future quarters.

Management highlighted the strong performance in EPS despite the lack of revenue guidance.

They expressed confidence in their ongoing projects and future potential.

Supernus Pharmaceuticals Beats on EPS, Stock Down 1.77%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Beats on EPS, Stock Down 1.77%

Key numbers

Management commentary